12-week 24/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: Effect on hemoglobin A1c and hypoglycemia
Diabetes Care Oct 19, 2017
Dassau E, et al. - A novel adaptive artificial pancreas (AP) was developed and tested by the consortium in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks. In hemoglobin A1c (HbA1c) and hypoglycemia, use of this novel adaptive AP yielded significant reductions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
